Celea has corralled $180 million to see if its twist on an approved medicine for idiopathic pulmonary fibrosis can beat the original Roche treatment.
With major backing from new investors, Celea Therapeutics hopes to follow in the footsteps of its siblings Seaport Therapeutics and Karuna Therapeutics.
Celea has corralled …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
A PureTech startup banks $180M for a new IPF drug
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Zymeworks acquires struggling Theravance for $929M
Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's…
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard…
Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat…
Full-Life Technologies gets $150M; Quince finds a new life; China biotech gets $50M; SERB Pharmaceuticals buys rights to Hansa…
Parabilis Medicines, the decade-old and well-funded
Pfizer CFO exits; GSK wins FDA nod for oral UTI drug; Apellis trial paused; plus Mersana ADC dropped, TORL ADC data, Corcept…
